02/25/2026
Axiom Brain Health Medical Director and Neurologist Dr. Susan Steen co-authored a recently published article in Nature Aging about the safety profile of Risvodetinib, an investigational drug for those with early and untreated Parkinson's Disease
Werner et al. present the results of the 201 Trial, a 12-week randomized, double-blind placebo-controlled phase 2a study of risvodetinib, in patients with early untreated Parkinson’s disease. Risvodetinib was found to be safe and well tolerated.